Mostrar el registro sencillo del ítem
Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials
dc.contributor.author | Sahebkar A. | |
dc.contributor.author | Simental-Mendía L.E. | |
dc.contributor.author | Pirro M. | |
dc.contributor.author | Montecucco F. | |
dc.contributor.author | Carbone F. | |
dc.contributor.author | Banach M. | |
dc.contributor.author | Barreto G.E. | |
dc.contributor.author | Butler A.E. | |
dc.date.accessioned | 2020-09-02T22:27:37Z | |
dc.date.available | 2020-09-02T22:27:37Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1080/07853890.2018.1495338 | |
dc.identifier.citation | 50, 6, 485-493 | |
dc.identifier.issn | 07853890 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/6136 | |
dc.description | Aims: To assess the effect of fibrates on circulating cystatin C levels. Material and methods: Clinical studies evaluating the effect of a fibrate on circulating cystatin C levels were searched in PubMed-Medline, SCOPUS, Web of Science, and Google Scholar databases. A random-effect model and generic inverse variance method were used for quantitative data synthesis, sensitivity analysis conducted using the leave-one-out method, and weighted random-effects meta-regression performed to evaluate potential confounders on cystatin C levels. Results: This meta-analysis of data from nine published studies (16 treatment arms) involved a total of 2195 subjects. In a single-arm analysis of clinical trials (without control group; eight studies comprising 14 treatment arms), fibrate therapy increased circulating cystatin C concentrations (WMD: 0.07 mg/dL, 95% CI: 0.04, 0.10, p <.001; I 2 = 82.66%). When the analysis was restricted to randomized controlled trials (four studies comprising six treatment arms), again elevation of circulating cystatin C levels was observed (WMD: 0.06 mg/L, 95% CI: 0.03, 0.09, p <.001; I 2 = 42.98%). Elevated cystatin C levels were only seen with fenofibrate and not with other fibrates. Conclusions: The results suggest that fenofibrate treatment adversely affects cystatin C levels and might partially explain the limited efficacy of fenofibrate in reducing cardiovascular events.Key message Fenofibrate treatment adversely affects cystatin C levels and might partially explain the limited efficacy of fenofibrate in reducing cardiovascular events. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. | |
dc.language.iso | en | |
dc.publisher | Taylor and Francis Ltd | |
dc.subject | cystatin C | |
dc.subject | fenofibrate | |
dc.subject | Fibrates | |
dc.subject | cystatin C | |
dc.subject | fenofibrate | |
dc.subject | fibric acid derivative | |
dc.subject | antilipemic agent | |
dc.subject | cystatin C | |
dc.subject | fibric acid derivative | |
dc.subject | low density lipoprotein cholesterol | |
dc.subject | peroxisome proliferator activated receptor alpha | |
dc.subject | PPARA protein, human | |
dc.subject | cardiovascular risk | |
dc.subject | drug efficacy | |
dc.subject | dyslipidemia | |
dc.subject | human | |
dc.subject | meta analysis | |
dc.subject | priority journal | |
dc.subject | protein blood level | |
dc.subject | randomized controlled trial (topic) | |
dc.subject | Review | |
dc.subject | risk reduction | |
dc.subject | systematic review | |
dc.subject | blood | |
dc.subject | cardiovascular disease | |
dc.subject | clinical trial (topic) | |
dc.subject | hypertriglyceridemia | |
dc.subject | metabolism | |
dc.subject | pathology | |
dc.subject | treatment outcome | |
dc.subject | Cardiovascular Diseases | |
dc.subject | Cholesterol, LDL | |
dc.subject | Clinical Trials as Topic | |
dc.subject | Cystatin C | |
dc.subject | Fibric Acids | |
dc.subject | Humans | |
dc.subject | Hypertriglyceridemia | |
dc.subject | Hypolipidemic Agents | |
dc.subject | PPAR alpha | |
dc.subject | Treatment Outcome | |
dc.title | Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials | |
dc.type | Review |